Targeting the TWEAK-exosomal miR-7 axis attenuates pressure overload induced cardiac remodelling and fibrosis

Background: Cardiac fibrosis contributes to the progression of pathological hypertrophy toward heart failure. However, the mechanisms underlying TWEAK-mediated cardiomyocyte-fibroblast crosstalk remain poorly understood. This study investigated the role of exosomal miR-7 in TWEAK-induced cardiac fibrotic remodeling. Methods: Cardiomyocytes were stimulated with recombinant TWEAK (200 ng/ml), and secreted exosomes were isolated and characterized. Exosomal uptake and profibrotic responses were evaluated in cardiac fibroblasts. The contribution of exosomal miR-7 was investigated using antagomiR-7 and GW4869-mediated inhibition of exosome secretion. Raf-1/AKT and TGF-β1/SMAD signaling were examined. Integrated transcriptomic and metabolomic profiling was performed using RNA sequencing and GC-MS. In vivo validation involved systemic administration of TWEAK-induced exosomes and pharmacological TWEAK inhibition using aurintricarboxylic acid (ATA) in a transverse aortic constriction (TAC) model. Results: Exosomes from TWEAK-stimulated cardiomyocytes were taken up by cardiac fibroblasts, enhancing migration and upregulating α-SMA and TGF-β1. TWEAK enriched miR-7 in these exosomes, raising miR-7 levels in recipient fibroblasts. Inhibiting miR-7 attenuated fibroblast activation, while blocking exosome secretion reduced miR-7 transfer and fibrotic responses. Mechanistically, miR-7 suppressed Raf-1/AKT signaling and enhanced TGF-β1/SMAD signaling. Multi-omics analyses revealed coordinated metabolic and transcriptomic remodeling, including altered energy metabolism, extracellular matrix pathways, and SMAD, PI3K, and hypoxia-related signaling. Systemic administration of miR-7-enriched exosomes exacerbated cardiac fibrosis in vivo, whereas ATA-mediated TWEAK inhibition in TAC reduced hypertrophy, fibrosis, and exosomal miR-7 levels. Conclusion: These findings establish a TWEAK-exosome-miR-7 axis as a mediator of cardiomyocyte-fibroblast crosstalk, identifying exosomal miR-7 as a key regulator of cardiac fibrotic remodeling and TWEAK as a potential therapeutic target.

Authors

Institutions

Publication Details

Journal
Authorea
Published
2026-11-20
DOI
https://doi.org/10.22541/authorea.15012557/v1
Primary Topic
Cardiac Fibrosis and Remodeling
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeting the TWEAK-exosomal miR-7 axis attenuates pressure overload induced cardiac remodelling and fibrosis

Kashif Hanif, Shishir Kumar Gupta, Prabha Burman, Pragya Bharati et al.
2 links
Authorea
Cardiac Fibrosis and Remodeling
preprint

Targeting the TWEAK-exosomal miR-7 axis attenuates pressure overload induced cardiac remodelling and fibrosis

Kashif Hanif, Shishir Kumar Gupta, Prabha Burman, Pragya Bharati, Manendra Singh Tomar, Kumaravelu Jagavelu, Baisakhi Moharana, Ashutosh Shrivastava, Azma Khatoon, Saumya Tripathi
preprint en

Abstract

Background: Cardiac fibrosis contributes to the progression of pathological hypertrophy toward heart failure. However, the mechanisms underlying TWEAK-mediated cardiomyocyte-fibroblast crosstalk remain poorly understood. This study investigated the role of exosomal miR-7 in TWEAK-induced cardiac fibrotic remodeling. Methods: Cardiomyocytes were stimulated with recombinant TWEAK (200 ng/ml), and secreted exosomes were isolated and characterized. Exosomal uptake and profibrotic responses were evaluated in cardiac fibroblasts. The contribution of exosomal miR-7 was investigated using antagomiR-7 and GW4869-mediated inhibition of exosome secretion. Raf-1/AKT and TGF-β1/SMAD signaling were examined. Integrated transcriptomic and metabolomic profiling was performed using RNA sequencing and GC-MS. In vivo validation involved systemic administration of TWEAK-induced exosomes and pharmacological TWEAK inhibition using aurintricarboxylic acid (ATA) in a transverse aortic constriction (TAC) model. Results: Exosomes from TWEAK-stimulated cardiomyocytes were taken up by cardiac fibroblasts, enhancing migration and upregulating α-SMA and TGF-β1. TWEAK enriched miR-7 in these exosomes, raising miR-7 levels in recipient fibroblasts. Inhibiting miR-7 attenuated fibroblast activation, while blocking exosome secretion reduced miR-7 transfer and fibrotic responses. Mechanistically, miR-7 suppressed Raf-1/AKT signaling and enhanced TGF-β1/SMAD signaling. Multi-omics analyses revealed coordinated metabolic and transcriptomic remodeling, including altered energy metabolism, extracellular matrix pathways, and SMAD, PI3K, and hypoxia-related signaling. Systemic administration of miR-7-enriched exosomes exacerbated cardiac fibrosis in vivo, whereas ATA-mediated TWEAK inhibition in TAC reduced hypertrophy, fibrosis, and exosomal miR-7 levels. Conclusion: These findings establish a TWEAK-exosome-miR-7 axis as a mediator of cardiomyocyte-fibroblast crosstalk, identifying exosomal miR-7 as a key regulator of cardiac fibrotic remodeling and TWEAK as a potential therapeutic target.

Authorea
Central Drug Research Institute (IN), King George's Medical University (IN), Centre of Biomedical Research (IN), Academy of Scientific and Innovative Research (IN)
Council of Scientific and Industrial Research, India
Good health and well-being
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon